Oronsky B, Knox S, Scicinski J. Trans. Onc. 2011, 4, 256
Six degrees of separation: The oxygen effect in the development of radiosensitizers
read more
Reviews
Is nitric oxide (NO) the last word in radiosensitization? A review
Oronsky B, Knox S, Scicinski J. Trans. Onc. 2012, 5, 66
Beyond antiangiogenesis: Vascular modulation as an anticancer therapy-a review
Oronsky B, Scicinski J, Reid T, Knox S. Trans. Onc. 2012, 5, 133
The scarlet letter of alkylation: A mini review of selective alkylating agents
Oronsky B, Reid T, Knox S, Scicinski J. Trans. Onc. 2012, 21, 226
Development of a safe and efficient two-step synthesis for preparing 1-bromoacetyl-3,3-dinitroazetidine, a novel clinical anticancer candidate
Straessler N, Lesley M, Cannizzo L. Org. Process Res. Dev. February 15, 2012, pp 512–517 DOI: 10.1021/op2003216
Episensitization: Therapeutic tumor resensitization by epigenetic agents: A review and reassessment
Oronsky B, Oronsky N, Knox S, Fanger G, Scicinski J. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1187-1198
Follow the ATP: Tumor energy production. a perspective
Oronsky B, Oronsky N, Fanger G, Parker C, Caroen S, Lybeck M, Scicinski J. Anticancer Agents Med Chem 2014;14(9):1187-98
Rewriting the epigenetic code for tumor resensitization: A review
Oronsky B, Oronsky N, Scicinski J, Fanger G, Lybeck M, Reid T. Trans. Onc. 2014, 7, 626-631
The war on cancer: A military perspective
Oronsky B, Carter C, Mackie V, Scicinski J, Oronsky A, Oronsky N, Caroen S, Parker C, Lybeck M, Reid T. Front Oncol. 2014; 4: 387
Episensitization: Defying time’s arrow
Oronsky B, Oronsky A, Lybeck M, Oronsky N, Scicinski J, Carter C, Day R, Rodriguez Orengo J, Rodriguez-Torres M, Fanger G, Reid T. Front Oncol. 2015 Jun 11;5:134
Going viral: A review of replication-selective oncolytic adenoviruses.
Larson C, Oronsky B, Scicinski J, Fanger G, Stirn M, Oronsky A, Reid T. Oncotarget. 2015 Aug 21;6(24):19976-89.
Confirmatory trials in the evaluation of anticancer medicinal products in man—PFS2: A measure of therapeutic action-at-a-distance
Oronsky B, Carter C, Reid T, Scicinski J, Oronsky A, Lybeck M, Caroen S, Stirn M, Oronsky N, Langecker P Neoplasia 2015, 17(9): 716-722
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies
Carter C, Zeman K, Day R, Richard P, Oronsky A, Oronsky N, Lybeck M, Scicinski J, Oronsky B. Oncotarget. 2016 Mar 19.
Rockets, radiosensitizers, and RRx-001: An origin story part I
Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S. Discov Med. 2016 Mar;21(115):173-80.
RRx-001, a novel dinitroazetidine radiosensitizer
Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S. Invest New Drugs. 2016 Jun;34(3):371-7.
“No patient left behind”: An alternative to “the war on cancer” metaphor
Oronsky B, Carter C, Oronsky A, Salacz M, Reid T. Med Oncol. 2016 Jun;33(6):55.
Turning on the radio: Epigenetic inhibitors as potential radiopriming agents.
Oronsky B, Scicinski J, Kim M, Cabrales P, Salacz M, Carter C, Oronsky N, Lybeck H, Lybeck M, Larson C, Reid T, Oronsky A. Biomolecules. 2016 Jul 4;6(3). pii: E32. doi: 10.3390/biom6030032.
RRx-001: A systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in phase II clinical trials.
Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox S, Peehl D, Zhao H, Ning S, Cabrales P, Summers T Jr, Reid T, Fitch W, Kim M, Trepel J, Lee M, Kesari S, Abrouk N, Day R, Oronsky A, Ray C, Carter C. Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi:...
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B, Ray C, Spira A, Trepel JB, Carter C, Cottrill H. Med Oncol. 2017 Jun;34(6):103. doi: 10.1007/s12032-017-0960-z. Epub 2017 Apr 25.
No patient left behind: The promise of immune priming with epigenetic agents.
Carter C, Oronsky B, Roswarski J, Oronsky A, Oronsky N, Scicinski J, Lybeck H, Kim M, Lybeck M, Reid T. Oncoimmunology. 2017 Aug 30;6(10):e1315486. doi: 10.1080/2162402X.2017.1315486. eCollection 2017.
Nitric oxide donor-based cancer therapy: advances and prospects
Huang Z, Fu J, Zhang Y. J Med Chem. 2017 Sep 28 doi: 10.1021/acs.jmedchem.6b01672.
What’s new in SCLC? A review.
Oronsky B, Reid T, Oronsky A, Carter C. Neoplasia. 2017 Oct;19(10):842-847. doi: 10.1016/j.neo.2017.07.007. Epub 2017 Sep 6.
Electrolyte disorders with platinum-based chemotherapy: Mechanisms, manifestations and management.
Oronsky B, Caroen S, Oronsky A, Dobalian V, Oronsky N, Lybeck M, Reid T, Carter C. Cancer Chemother Pharmacol. 2017 Nov;80(5):895-907. doi: 10.1007/s00280-017-3392-8. Epub 2017 Jul 20.
Nothing but NET: A review of neuroendocrine tumors and carcinomas.
Oronsky B, Ma P, Morgensztern D, Carter C. Neoplasia. 2017 Dec;19(12):991-1002. doi: 10.1016/j.neo.2017.09.002. Epub 2017 Nov 5.
A review of clinical radioprotection and chemoprotection for oral mucositis
Oronsky B, Burbano E, Kim M, Oronsky N, Lybeck M, Goyal S, Cabrales P, Caroen S, Oronsky A, Carter C. Translational Oncology. Apr 2018.
A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)
Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, Hedjran F, Carter C, Reid T. OncoImmunology, 2018, Jul 23.